Eli Lilly Business Development Head Reveals Strategic Focus on Late-Stage Metabolic Assets

Eli Lilly's head of business development disclosed the pharmaceutical giant's preference for acquiring late-stage metabolic disease assets over early-stage research programs during an interview on STAT News' "The Readout LOUD" podcast this week. The executive outlined how Lilly evaluates potential deals to complement its dominant GLP-1 franchise built around tirzepatide (Mounjaro, Zepbound).

According to STAT's podcast, Lilly's deal strategy prioritizes companies with clinical-stage programs that address complications of obesity and diabetes, reflecting the company's intent to build a comprehensive metabolic health ecosystem beyond weight loss medications.

The podcast also covered two major recent developments in biotechnology that could impact metabolic disease treatment. Allogene Therapeutics provided updates on its off-the-shelf CAR-T cell therapy platform, which has enrolled patients in Phase 2 trials for blood cancers and aims to reduce manufacturing costs from hundreds of thousands of dollars per treatment to potentially tens of thousands.

Merck's $2.7 billion acquisition of Terns Pharmaceuticals, completed earlier this month, featured prominently in the discussion. The deal gives Merck control of Terns' lead asset TERN-501, a thyroid hormone receptor beta agonist in Phase 3 trials for non-alcoholic steatohepatitis (NASH). Merck paid $10.75 per share for Terns, representing a 46% premium over the company's closing price before acquisition rumors surfaced.

Terns' pipeline also includes TERN-601, a GLP-1 receptor agonist in Phase 2 development for NASH, putting Merck in direct competition with Lilly's own liver disease research. The acquisition reflects growing pharmaceutical industry interest in NASH, a liver condition affecting up to 25% of adults globally and closely linked to obesity and type 2 diabetes.

Lilly's strategic focus on late-stage acquisitions suggests the company wants to quickly expand treatment options for patients already using tirzepatide who may develop related health complications. This approach typically costs more upfront but reduces the 10-15 year timeline normally required to bring new drugs to market.

The business development insights come as Lilly reports record revenues from tirzepatide, with obesity indication Zepbound generating over $1 billion in sales during its first year. This financial strength positions the company to compete aggressively for acquisition targets in metabolic disease.

For patients currently using GLP-1 medications like tirzepatide or semaglutide, Lilly's deal strategy signals potential access to combination therapies that address multiple aspects of metabolic syndrome. Rather than taking separate medications for diabetes, weight management, and liver health, future treatment regimens could integrate these approaches through strategic partnerships or acquisitions.

The focus on late-stage assets means patients might see new treatment options sooner than traditional drug development timelines would suggest, particularly for managing complications like NASH that can develop in people with long-term obesity or diabetes.